How GLP-1 Medications Are Reshaping Digital Health and Fitness

One in eight American adults is now taking a GLP-1 medication [1]. That number has more than doubled since early 2024. Combined global sales of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are projected to exceed $84.5 billion in 2026, making GLP-1 therapies the top-selling drug class in the world [2].

This isn’t just a pharmaceutical story. The downstream effects of tens of millions of people losing significant weight through medication — while facing real risks like muscle loss and cardiovascular changes — are reshaping the fitness industry, creating an entirely new category of digital health products, and generating demand for behavioral and health data that didn’t exist two years ago.

For product teams building health, fitness, and wellness apps, GLP-1 represents both a massive addressable market and a fundamental shift in what users need from health technology.

The scale of the shift

The numbers are difficult to overstate.

Approximately 33 million U.S. adults are now taking or have recently taken a GLP-1 drug [1]. Usage skews toward adults ages 50–64 (22% currently taking), women (15% vs. 9% of men), and those with diagnosed conditions — 45% of adults with diabetes and 23% of those with obesity are currently on GLP-1 therapy [1].

On the pharmaceutical side, Eli Lilly holds roughly 60% of the U.S. GLP-1 market, with Mounjaro and Zepbound generating $36.5 billion in 2025 revenue alone [2]. Novo Nordisk’s semaglutide products are projected at $39.5 billion in 2026 sales [2]. The broader obesity drug market is projected to reach $95 billion by 2030 [3].

But the more relevant signal for health technology is this: these are highly motivated, health-conscious consumers who are actively seeking tools to complement their medication. They’re tracking their weight, monitoring side effects, adjusting their nutrition, and — critically — being told by their doctors to exercise more. They represent a new user segment that is simultaneously medically engaged and digitally active.

The muscle loss problem

GLP-1 drugs are highly effective for weight reduction — 90% of users in a 12-week wearable-tracked study achieved at least 5% weight loss, with an average reduction of 10% body weight [4]. But weight loss from GLP-1 therapy is not purely fat loss.

Research published in Acta Diabetologica confirms that clinical trials consistently show GLP-1-driven weight reduction is accompanied by decreased lean body mass [5]. Users can lose as much muscle in 12–18 months of GLP-1 therapy as they would naturally over a decade [4].

This isn’t a minor side effect. Muscle mass is foundational to metabolic health, functional independence, bone density, and long-term mortality risk. Losing it at an accelerated rate while losing weight undermines the long-term health benefits the medication is supposed to provide.

The clinical consensus is clear: GLP-1 therapy without concurrent exercise — particularly resistance training — carries meaningful health risks. This creates a direct product opportunity for fitness and health technology.

What the wearable data shows

The first large-scale study using wearable data to track GLP-1’s physiological effects was published in the American Journal of Physiology - Heart and Circulatory Physiology in 2025, conducted in collaboration with WHOOP [4][6].

The study followed 132 participants (66 on GLP-1 medications, 66 matched controls) over 12 weeks, using continuous wearable monitoring. Key findings:

Cardiovascular effects: GLP-1 users experienced a 3 bpm increase in resting heart rate and a 6 ms decrease in heart rate variability [4]. Both changes indicate increased cardiovascular strain — HRV depression in particular signals reduced autonomic recovery capacity.

Exercise as mitigation: Participants who exercised more experienced smaller increases in resting heart rate, suggesting that physical activity directly counteracts the cardiovascular side effects of GLP-1 therapy [4][6].

Activity increase: GLP-1 users increased physical activity by an average of 30 minutes per week compared to baseline [4] — suggesting the medication itself may facilitate greater activity through weight reduction and improved energy.

The implication for health technology is direct: continuous monitoring of cardiovascular markers (HRV, resting heart rate) and activity levels is clinically relevant for GLP-1 users, not just a wellness feature. The wearable data provides signals that inform whether the medication’s benefits are being supported or undermined by the user’s behavior.

How the fitness industry is adapting

The fitness industry’s response to GLP-1 has been rapid. About 50% of GLP-1 users consider gym membership, and as of early 2026, at least 17 fitness clubs have launched dedicated GLP-1 programs [7].

The integration models span a wide spectrum:

Adapted programming — Equinox and similar premium clubs are redesigning workouts specifically for GLP-1 users, emphasizing resistance training for muscle preservation and progressive overload protocols that account for rapid body composition changes [7].

Telehealth referral partnerships — Planet Fitness partnered with Ro, connecting gym members to GLP-1 prescribing services. This model treats the gym as a distribution channel for medication access [7].

Bundled programs — F45 partnered with Dr. B to offer GLP-1 prescriptions bundled with group fitness. FuturHealth provides an all-in-one app combining GLP-1 medications, meal delivery, Apple Fitness+ access, and dietitian coaching — members on the full program lost 58.5% more weight than medication alone [8].

In-clinic prescribing — Life Time, Monarch, and Love.Life have brought prescribing in-house, offering GLP-1 therapy directly within the fitness facility alongside training and nutrition services [7].

The common thread across all models: exercise is no longer optional context for weight loss — it’s a medical necessity for GLP-1 users. And the data to track whether exercise is sufficient (activity volume, strength progression, body composition changes) is precisely what health and fitness technology provides.

The new product category: medication-plus-behavior

A wave of digital products is emerging at the intersection of GLP-1 medication management and behavioral health data.

Dedicated GLP-1 companion apps

Apps like Dosio, GLP1+, Dose Up, and Metra Health AI have launched specifically for GLP-1 users [9]. Common features include injection/dose tracking, side effect logging, weight and progress tracking, nutrition monitoring with protein emphasis, and integration with Apple Health and Health Connect.

The more sophisticated offerings — like GLP1+ with its AI coaching and Metra Health with its pharmacokinetic modeling — are moving beyond simple logging toward adaptive guidance that responds to the user’s data.

Integrated telehealth platforms

Platforms like FuturHealth and Fridays combine medication access with comprehensive behavioral support: dietitian coaching, fitness programming, meal planning, and health data tracking [8]. These platforms recognize that the medication alone isn’t enough — sustained outcomes require behavioral change that persists after (or alongside) the prescription.

What’s missing

Most current GLP-1 apps focus on medication logistics (dose reminders, symptom logging) and basic weight tracking. What’s largely absent — and what the clinical evidence suggests is most important — is integration with continuous health and activity data:

• Real-time activity monitoring to ensure sufficient exercise volume for muscle preservation
• HRV and resting heart rate tracking to monitor cardiovascular effects
• Sleep data to assess recovery quality (GLP-1 can disrupt sleep patterns during dose titration)
• Strength and body composition trends over weeks and months, not just scale weight
• Behavioral archetypes that reveal whether the user’s lifestyle is supporting or undermining the medication’s effects

The gap between what GLP-1 users clinically need and what current apps provide is where the next generation of products will be built.

What this means for health product teams

A large, motivated, and growing user segment

Twelve percent of U.S. adults — and growing — represents a user base that is actively seeking digital health tools, willing to pay for them, and medically motivated to engage. GLP-1 users aren’t casual wellness trackers; they’re managing a medical intervention and need tools that help them do it well.

Behavior data becomes clinically relevant

For GLP-1 users, activity data isn’t a vanity metric — it’s clinically meaningful. Whether someone is doing enough resistance training to preserve muscle mass, whether their cardiovascular markers are trending in the right direction, whether their sleep is supporting recovery — these are questions that affect medical outcomes. Health data infrastructure that can answer them has direct clinical value.

The medication-behavior feedback loop

The most effective GLP-1 outcomes come from the combination of medication and behavior change. Products that can close the loop — connecting medication data with behavioral data and delivering adaptive guidance — will outperform products that treat medication and behavior as separate tracks.

Nutrition shifts

GLP-1 suppresses appetite, often dramatically. Users need to ensure adequate protein intake (to mitigate muscle loss) despite eating significantly less. Nutrition tracking features that emphasize protein targets, meal quality over calorie restriction, and macronutrient balance are directly relevant to this population — and distinct from traditional diet app features.

Where this is heading

Clinical-grade companion experiences. As GLP-1 prescribing expands, payers and providers will demand evidence that companion programs improve outcomes. Products that combine wearable health data with medication adherence tracking to demonstrate measurable benefit — reduced muscle loss, maintained cardiovascular health, sustained weight management — will have a regulatory and commercial advantage.

Post-medication retention. Roughly 14% of GLP-1 users have already stopped due to cost [1], and discontinuation rates are a major concern. Products that help users maintain weight loss and health gains after stopping medication — through behavioral habits, activity monitoring, and coaching — address a critical unmet need.

Insurance and employer integration. With obesity-related healthcare costs running into hundreds of billions annually, insurers and employers have strong incentives to fund GLP-1 programs that include behavioral monitoring and exercise requirements. Health data that demonstrates program adherence and outcome improvement will be central to these models.

Beyond weight loss. GLP-1 research is expanding into cardiovascular protection, kidney disease, addiction, and neurodegeneration. Each new indication creates a new population of users who need behavioral monitoring and health data tracking alongside their medication. The product patterns being established now for weight management will extend across these future use cases.

The GLP-1 wave is not a trend that health technology can sit out. When one in eight adults is taking a medication that requires behavioral monitoring to be safe and effective, the products that bridge medication and behavior will define the next chapter of consumer health.